LEAD-6 Study Shows Better Results With Liraglutide Than Exenatide In Controlling Blood Glucose In Type 2 Diabetes
LEAD-6 Study Shows Better Results With Liraglutide Than Exenatide In Controlling Blood Glucose In Type 2 Diabetes
The results of the LEAD-6 study are published in an article Online First and in a future edition of The Lancet. The findings are presented at the same time at the American Diabetes Association meeting in New Orleans, USA. They indicate that taking liraglutide once a day is more efficient in controlling blood glucose in type 2 diabetes than the presently marketed treatment - two doses a day of exenatide.